Vigora is indicated for the treatment of pulmonary arterial hypertension in adults to improve exercise ability and delay clinical worsening. The delay in clinical worsening was demonstrated when Vigora was added to background epoprostenol therapy. Studies establishing effectiveness were short-term associated with connective tissue disease Limitation of Use Adding Vigora to bosentan therapy does not result in any beneficial effect on exercise capacity.
| https://www.onemedz.com/product/vigora/ |
| https://www.onemedz.com/ |
Replies